Prenatal Dex Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

354 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-04

Study Completion Date

2025-06-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The classic form of 21-hydroxylase deficiency (prevalence 1/15,000) is the most common cause of congenital adrenal hyperplasia (CAH). This autosomic recessive disease is responsible for virilization of the external genitalia in girls through androgen hypersecretion during fetal life. Since 1984, the Lyon Pediatric Endocrinology group has proposed prenatal dexamethasone (DEX) for all fetuses at risk of CAH With the aim of preventing fetal androgen hypersecretion in affected girls and avoiding poor long-term results from reconstructive surgery. Prenatal DEX was used in Europe and the USA but its use was recently suspended: in 2007, a Swedish study conducted on 26 children treated with DEX in utero for a short period of time reported cognitive impairments. These data were not confirmed by an American study on the short-term DEX use, which showed potential cognitive impairments in CAH children exposed to DEX for long periods of time. These confusing and controversial results have caused the scientific community to question its position and have resulted in the suspension of the use of prenatal DEX with drastic consequences for CAH girls (virilization; genital surgery etc.). In this context, an evaluation of neuropsychological development under in utero DEX is essential to validate its indication for use during the prenatal period. This study will evaluate outcomes using prospective cognitive and emotional assessments. It will first focus on the unaffected children previously treated in utero in order to assess the adverse effects of the drug. The study will then assess the children with CAH for whom DEX could have beneficial effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers

NCT00617292

Adrenal Hyperplasia, Congenital

UNKNOWN

Dexamethasone and Pregnancy: Maternal Effects

NCT06259994

Dexamethasone During Pregnancy

RECRUITING

A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+)

NCT06350565

Respiratory Distress Syndrome of Newborn

NOT_YET_RECRUITING NA

Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth

NCT02897076

Neonatal Complications

COMPLETED PHASE3

Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction

NCT02672566

Fetal Growth Retardation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Adrenal Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group D+ 1

Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.

Group Type EXPERIMENTAL

Neuropsychological and cognitive assessment

Intervention Type BEHAVIORAL

Group D+ 2

Girls and boys affected by CAH and treated in utero by Dexamethasone.

Group Type EXPERIMENTAL

Neuropsychological and cognitive assessment

Intervention Type BEHAVIORAL

: Group D - 1

Girls and boys not affected by CAH and not treated in utero by Dexamethasone.

Group Type ACTIVE_COMPARATOR

Neuropsychological and cognitive assessment

Intervention Type BEHAVIORAL

Group D - 2

Girls and boys affected by CAH and not treated in utero by Dexamethasone.

Group Type ACTIVE_COMPARATOR

Neuropsychological and cognitive assessment

Intervention Type BEHAVIORAL

Group D - 3

Girls and boys enrolled in school closed to Lyon

Group Type OTHER

Neuropsychological and cognitive assessment

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuropsychological and cognitive assessment

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Groups D+1, D+2, D-1 and D-2

* Male or female
* Patient with Congenital Adrenal Hyperplasia or sibling of a CAH patient
* Age: 6 to 15 years (at the time of inclusion)
* The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
* Subject with health insurance

Group D-3 (Schoolchildren)

* Male or female
* With no connection with Congenital Adrenal Hyperplasia
* Age: 6 to 15 years (at the time of inclusion)
* The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
* Subject with health insurance

Exclusion Criteria

For all groups :

* Patient/Subject with another genetic disease
* Patient/Subject with known neuropsychology disease(s)
* Patient/Subject whose mother has received another treatment during her pregnancy with possible known adverse events on the neuropsychological development of the child

Minimum Eligible Age

6 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes